COSM vs MCK: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
COSM and MCK are similarly sized, but COSM trades noticeably cheaper on forward earnings (3.08x vs 17.00x): the market is paying up for MCK's profile and pricing COSM more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
COSM vs MCK: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | COSM | MCK | What it tells you |
|---|---|---|---|
| Forward P/E | 3.08 | 17.00 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 4.15 | 0.31 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 5% of range | 61% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: COSM is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how COSM and MCK affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COSM and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COSM and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Cosmos Health (COSM) do?
Cosmos Health Inc. is a small, vertically integrated global healthcare group headquartered in Greece and listed on Nasdaq under COSM. Its business has two broad parts. The larger, established part distributes pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter medicines, to retail pharmacies and wholesalers through subsidiaries in Greece and the UK. The second, higher-margin part is a portfolio of proprietary brands, most importantly the Sky Premium Life nutraceutical and supplement line, plus names like Mediterranation, bio-bebe, NOOR Collagen, and the C-Sept and C-Scrub lines. The strategy is to grow the branded, owned-product side, which carries better margins than pure distribution, while expanding into new markets and categories such as skincare and prescription medicines.
What does McKesson Corporation (MCK) do?
McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.
COSM vs MCK: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- COSM drivers: Revenue growth and 2029 targets; Branded products and margin mix.
- MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The overriding risks are financial and structural rather than operational. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.
COSM or MCK: which should you pick?
COSM vs MCK: the full fundamentals
COSM. Figures are approximate and tied to the asOf date; verify live numbers before acting. Because Cosmos is lossmaking, price-to-earnings multiples do not apply, and the market values it mainly on revenue growth and the credibility of its 2029 targets rather than current profit. Share counts have shifted with past issuance and a prior reverse split, so market cap and per-share figures should be checked live. For a sub-$1 micro-cap facing a listing deadline, capital-structure and delisting risk matter more to the stock than any single quarter's sales.
MCK. All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.
Headline figures (approximate, Jul 2026): COSM shows revenue (2025 full year) ~$65 million, up roughly 20% year over year, revenue (2026 quarterly) Q1 2026 ~$17.9 million, up ~31%; Q2 2026 guided to roughly $19 million, profitability Still net lossmaking; full-year 2025 net loss on the order of $19 million, long-term guidance Management targets ~$200 million revenue and positive adjusted EBITDA by 2029 (aspirational, far above current results); MCK shows revenue (fy2026) ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live), segment profit mix North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate), margin profile Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins, earnings trend Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures).
The bottom line: COSM vs MCK
COSM and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COSM and MCK exposure against your real portfolio. It is not an investment adviser.
Wondering how COSM or MCK fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Cosmos Health with AI
Connect the broker you already use and ask Walnut's AI how COSM fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between COSM and MCK?
+
Cosmos Health Inc. McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is COSM or MCK the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, COSM or MCK?
+
On forward P/E (as of August 2026), COSM trades at 3.08x and MCK at 17.00x, so COSM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both COSM and MCK?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of COSM vs MCK?
+
COSM: The overriding risks are financial and structural rather than operational. Cosmos is lossmaking despite growing revenue, so it depends on continued execution and, potentially, more capital to fund expansion. Its history of reverse stock splits, including a 1-for-25 split in 2022, and past share issuance means dilution has repeatedly hurt long-term holders, and further dilution or another reverse split is a live possibility. The stock trades well below $1 and faces a Nasdaq minimum-bid-price deadline in late 2026; failure to regain compliance could lead to delisting, which would sharply reduce liquidity and visibility. As a micro-cap, the shares are thinly traded and highly volatile, and press-release-driven news flow can move the price far more than fundamentals justify. Multi-year guidance toward roughly $200 million in revenue is aspirational and far above current results, so there is meaningful risk it is not met. MCK: The central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results. Customer concentration is real, with a few very large retail-pharmacy customers representing a big share of revenue, giving those partners negotiating leverage. Drug-pricing politics and policy (Medicare negotiation, PBM reform, importation proposals) create ongoing regulatory uncertainty. McKesson also carries a legacy of multibillion-dollar opioid-distribution settlements, and future litigation or regulatory action remains a tail risk. Execution on the Medical-Surgical separation and on integrating oncology and specialty acquisitions adds transition risk on top of the steady core.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell COSM or MCK; figures are approximate and dated (as of August 2026). Verify current data before investing.